secwatch.observer — SEC 8-K summary
======================================

Issuer:     MACROGENICS INC (MGNX)
CIK:        0001125345
Form:       8-K
Filed at:   2023-02-14T23:59:59+00:00
Accession:  0001125345-23-000021
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

MacroGenics reports preliminary Phase 1 lorigerlimab data; 28.6% PSA50 in mCRPC
-------------------------------------------------------------------------------

- 12 of 42 mCRPC patients (28.6%) achieved ≥50% PSA reduction; 9 of 42 (21.4%) achieved ≥90% PSA reduction.
- 9 of 35 evaluable patients (25.7%) had confirmed partial responses; median duration 4.6 months.
- TRAEs in 86.6% of patients; grade ≥3 TRAEs in 34.6%; 24.4% discontinued due to AEs; no fatal TRAEs.
- Company plans to initiate Phase 2 study in mCRPC in 2023.
- Median prior therapies: 2; 83% had prior docetaxel, 81% prior androgen receptor antagonist.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1125345/000112534523000021/0001125345-23-000021-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1125345/000112534523000021/mgnx-20230213.htm
  HTML page:      https://secwatch.observer/filing/0001125345-23-000021

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer